Enteris Biopharma Inc., of Boonton, N.J., said it entered a new agreement for continued clinical testing with development partner Cara Therapeutics Inc., of Shelton, Conn., involving Cara's peripherally selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.